Want to promote your SPRx services and connect with 11,000 SPRx professionals? Contact us.
Don’t miss this (and, it’s Free to attend!): 1st Virtual Conference in our industry! Real-World Evidence ideas from Pfizer, Baxter, HealthCore, BCBS, and more! Register today for 1st VIRTUAL Summit on Real World Evidence Needs and Practical Success Strategies: A Multi-Stakeholder Perspective
|IN THIS ISSUE|
|Most complete Jobs, Conferences, and Webinars list anywhere. Need to add one? Click Here.|
|SPOTLIGHT 1 OF THE WEEK||SPOTLIGHT 2 OF THE WEEK|
|Meet Sovaldi’s New Sidekick: Harvoni.|
The FDA recently announced its approval of Gilead Sciences’ hepatitis C combination drug Harvoni to be used with Sovaldi is the first oral combination therapy approved for Hep C, as well as the first regimen that does not need to be administered with interferon or ribavirin. Harvoni will be priced at $94,500 for a standard 12-week course. (Source: FirstWord Pharma, 10/10/14).
|Will The Majority Of Future Drugs Meet Orphan Drug Criteria?|
Orphan Drug Market Access: Payer Insights on the Present and Future is a report that examines the regulation, pricing, reimbursement, players and stakeholder/payer interests that are shaping the current and future direction of the orphan drug sector. This report offers insights from US and European healthcare payers and includes illustrative case studies that highlight key aspects of the orphan drug market. (Source: FirstWord, October 2014).
|Don’t Miss The Nation’s Largest Specialty Pharmacy Conference. Register Today!|
Registration is now open for Armada’s 2015 Specialty Pharmacy Summit & Expo to be held in Wynn Las Vegas, May 4-8, 2015. Guarantee your conference rate and reserve today! (Source: Armada Health Care, 2014).
|Do Specialty Drugs Offer Reasonable Value For Money?|
The high prices of specialty drugs has a lot of people questioning whether their cost is worth the clinical benefits they provide. A recent study in Health Affairs, looked at all specialty and traditional drugs approved by the FDA from 1999 to 2011, their additional health gains (QALYs), and increased costs incurred. This is said to be the first study to systematically compare specialty and traditional drugs in this way.
|How Has The Rise Of Specialty Pharmaceuticals Impacted Consumers?|
Given the unabated rise of SPRx, issues related to cost and access are set to dominate health policy discussions. The most recent edition of Health Affairs, published online on October 6, contains a handful of papers authored by academic and industry researchers offering different perspectives, including a report from researchers at Duke University who analyzed the real-world impact expensive specialty drugs are having on insurance premiums, while also offering new theories on best practices for cost-sharing methods. (Source: FirstWord Pharma).
|Specialty Pharmacy Trends Report: Oncology.|
First Report Managed Care partnered with the National Association of Specialty Pharmacy to put together this Specialty Trends Report. (Source: First Report Managed Care, 9/22/14)
|Specialty Pharmacy Trends Report: Multiple Sclerosis.|
This First Report Managed Care report takes a look at specialty pharmacy trends in Multiple Sclerosis thru the results of a survey. (Source: First Report Managed Care, 8/19/14).
|Specialty Pharmacy Trends Report: HIV/AIDS.|
First Report Managed Care conducted a survey to gain insight into the specialty pharmacy market as it relates to managed care decision-making and formularies. First Report Managed Care partnered with the National Association of Specialty Pharmacy bringing you this Specialty Pharmacy Trends. (Source: Evolve Beyond the Page, 8/19/14).
|Save The Date: Specialty Data Optimization Summit.|
This Summit takes place on December 11th in Philadelphia and will arm attendees with knowledge and actionable takeaways on how to unlock the power of specialty data to make informed, targeted decisions that take ROI to the next level. (Source: CBI).
|Updated HTA Decision Map: How Are New Products Faring With Authorities In Europe, Canada and More .|
Xcenda’s Decision Map makes it easy to stay informed on key Health Technology Assessments (HTA) decisions. Use their filters to find detailed information on product decisions in Australia, Canada, France, Germany, and the United Kingdom. (Source: Xcenda).
|Featured Jobs||Featured Webinars|